Algert Global LLC Purchases 4,622 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Algert Global LLC boosted its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 16.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 32,706 shares of the company’s stock after acquiring an additional 4,622 shares during the quarter. Algert Global LLC owned approximately 0.05% of Kymera Therapeutics worth $976,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its holdings in shares of Kymera Therapeutics by 18.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after purchasing an additional 996,300 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Kymera Therapeutics by 19.2% during the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock worth $191,635,000 after acquiring an additional 769,486 shares in the last quarter. Artal Group S.A. increased its holdings in shares of Kymera Therapeutics by 19.6% during the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after acquiring an additional 496,400 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Kymera Therapeutics by 229.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 674,655 shares of the company’s stock valued at $17,177,000 after acquiring an additional 469,947 shares in the last quarter. Finally, Jennison Associates LLC acquired a new stake in Kymera Therapeutics in the 1st quarter worth approximately $17,122,000.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $43.06 on Friday. The company has a 50-day moving average of $45.95 and a 200-day moving average of $39.52. Kymera Therapeutics, Inc. has a 52 week low of $9.60 and a 52 week high of $53.27. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of -17.16 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.10. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The firm had revenue of $25.60 million during the quarter, compared to analysts’ expectations of $12.55 million. During the same quarter last year, the company earned ($0.67) earnings per share. The company’s revenue for the quarter was up 55.2% compared to the same quarter last year. Sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.87 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the company. Morgan Stanley increased their price target on Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a report on Wednesday, August 14th. Wolfe Research upgraded shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, August 26th. Oppenheimer upped their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, September 27th. Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Finally, B. Riley increased their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, July 9th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.00.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the transaction, the director now directly owns 723,246 shares in the company, valued at $27,635,229.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the transaction, the director now directly owns 723,246 shares in the company, valued at $27,635,229.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jared Gollob sold 23,145 shares of the company’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $45.81, for a total transaction of $1,060,272.45. Following the sale, the insider now directly owns 95,470 shares in the company, valued at $4,373,480.70. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 495,605 shares of company stock valued at $19,303,364 in the last 90 days. 15.82% of the stock is owned by corporate insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.